John Donoghue, Ph.D Is Appointed to PathMaker Neurosystems Board

PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, welcomes John Donoghue, Ph.D. to the Company’s Board of Directors. John Donoghue was most recently Founding Director of the Wyss Center for Bio and NeuroEngineering in Geneva, Switzerland where he led the Center’s research activities and translational research programs focused on advanced neurotechnology.

“We are incredibly pleased that John Donoghue is joining PathMaker’s Board of Directors,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “As a world leader in both fundamental and translational neuroscience, he brings a rare perspective built on institutional leadership, entrepreneurial experience, and neurotechnology device development that will be instrumental as we expand the clinical applications of our proprietary technology platform.”

“PathMaker’s technology platform has breakthrough potential as a novel therapeutic device.  PathMaker has made strong progress and is nearing launch of their first product.   I am delighted to be joining the Board of Directors at such a significant time,” commented Dr. Donoghue. “The Company’s non-invasive approach to treating a wide range of neurological disorders using multi-site neuromodulation leverages decades of progress in neuroscience.   It is very exciting to see this technology advance towards market launch. PathMaker’s commitment to this innovative therapy promises to improve the lives of millions of people living with disabling neurological disorders.”

Prof. Donoghue is an internationally recognized neuroscientist who works at the forefront of neural devices and brain function. He has been Professor of Neuroscience and Engineering at Brown University for over 35 years, where he was the founding Chairman of the Department of Neuroscience and Founder of Brown University’s Carney Brain Science Institute. Before becoming the inaugural Director of the Geneva based Wyss Center for Bio- and NeuroEngineering in 2014, he also co-founded Cybernetics Neurotechnology Systems, a pioneering startup in the field of neuroprosthetics that developed the BrainGate brain-computer interface for people with paralysis. Donoghue has authored over 125 scientific publications and is a member of the National Academy of Medicine. His many honors and awards include the Erwin Schroedinger Prize, the Roche-Nature Medicine Prize, the Israel Brain Prize, and the International Prize for Translational Neuroscience.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution